RETA - Reata Pharmaceuticals, Inc.
| Previous Close | 42.84 |
| Open | 42.50 |
| Bid | 1.00 x 1200 |
| Ask | 0.00 x 900 |
| Day's Range | 42.01 - 44.50 |
| 52 Week Range | 19.31 - 44.56 |
| Volume | 266,353 |
| Avg. Volume | 229,579 |
| Market Cap | 1.144B |
| Beta | 0.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.99 |
| Earnings Date | Aug 9, 2017 - Aug 14, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 55.00 |
- Zacks•22 hours ago
Can The Uptrend Continue for Reata Pharmaceuticals (RETA)?
Investors certainly have to be happy with Reata Pharmaceuticals, Inc. (RETA) and its short term performance.
- GlobeNewswire•8 days ago
Reata Receives Orphan Drug Designation from the European Commission for Omaveloxolone for the Treatment of Friedreich’s Ataxia
Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced that the European Commission has granted orphan drug designation for omaveloxolone for the treatment of Friedreich’s ataxia (FA), based on the positive opinion from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA). Last year, Reata reported results from part 1 of MOXIe, a two-part, international, multi-center, randomized, double-blind, placebo-controlled Phase 2 trial studying the safety and efficacy of omaveloxolone in patients with FA. Treatment of FA patients with omaveloxolone produced dose- and time-dependent improvements in their modified Friedreich’s Ataxia Rating Scale (mFARS) scores, which are a measure of the neurologic function of FA patients. Reata is currently enrolling approximately 100 FA patients in the registrational part 2 portion of MOXIe and expects to have results in the second half of 2019.
- GlobeNewswire•28 days ago
Reata Announces Initiation of a Phase 1 Trial of RTA 1701, a Selective, Oral Allosteric Inhibitor of RORγt
Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced the initiation of a Phase 1 clinical trial of Reata’s RTA 1701, a highly selective and orally bioavailable allosteric RORγt inhibitor. This Phase 1, first-in-human study is evaluating the safety and pharmacokinetics of RTA 1701 in healthy volunteers and assessing ex vivo suppression of IL-17A secretion. Initial results are expected in the first half of 2019.
- GlobeNewswire•last month
Reata Pharmaceuticals, Inc. Secures $125 Million Term Loan Facility
Reata Pharmaceuticals, Inc. (RETA) (“Reata” or “the Company”), a clinical-stage biopharmaceutical company, today announced that it entered into an amended and restated loan and security agreement with Oxford Finance LLC and Silicon Valley Bank, which increased the Company’s term loan facility from $45 million to $125 million. Proceeds from the loan will be utilized primarily to support Reata’s multiple Phase 2 and 3 clinical trial programs for bardoxolone methyl and omaveloxolone.
- GlobeNewswire•last month
Reata Announces That Kyowa Hakko Kirin Initiated Ayame, a Phase 3 Trial of Bardoxolone Methyl for the Treatment of Diabetic Kidney Disease
Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced that its licensee, Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin), has initiated a Phase 3 clinical study, AYAME, to assess the efficacy and safety of bardoxolone methyl (bardoxolone) for the treatment of diabetic kidney disease in Japan. AYAME is a multi-center, randomized, double-blind, placebo-controlled Phase 3 trial enrolling an estimated 700 diabetic kidney disease patients with CKD stage G3 or G4. The primary efficacy endpoint is time to onset of a ≥ 30% decrease in estimated glomerular filtration rate (eGFR) from baseline or end-stage renal disease (ESRD). Secondary endpoints include time to onset of a ≥ 40% or ≥ 53% decrease in eGFR from baseline or ESRD, time to onset of ESRD, and change from baseline in eGFR at each evaluation time point. The estimated study completion date is March 2022.
- GlobeNewswire•2 months ago
Reata Selected to Present Early-Stage Programs at the BIO International Convention
Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced that Chief Development Officer, Keith Ward, Ph.D., will present at the Annual BIO International Convention on Wednesday, June 6, 2018, at 1:00 p.m. ET in Boston, MA. The BIO International Convention is a premier partnering-focused event for the biopharmaceutical industry, and Reata’s selection as a presenting company highlights the strength of its early-stage assets, including RTA 901 and RTA 1701. RTA 901 is a highly potent and selective C-terminal inhibitor of Hsp90, which has a critical role in mitochondrial function, protein folding, and inflammation. RTA 901 demonstrates profound efficacy in a wide range of animal models of neurologic disease, including diabetic neuropathy and demyelinating nerve injury. RTA 901 has been evaluated in a Phase 1 clinical trial in healthy volunteers, with no safety or tolerability issues and with an acceptable pharmacokinetic profile.
- Benzinga•2 months ago
Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 31) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) (Piper Jaffray initiated ...
- GlobeNewswire•2 months ago
Reata Announces Orphan Drug Designation From the European Commission for Bardoxolone Methyl for the Treatment of Alport Syndrome
Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced that the European Commission (EC) has granted orphan drug designation, based on the positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), for bardoxolone methyl (bardoxolone) for the treatment of Alport syndrome.
- ACCESSWIRE•2 months ago
Wired News - Reata Pharma Presented Encouraging Interim Data from PHOENIX Trial Assessing Bardoxolone Methyl in Patients with ADPKD and IgA Nephropathy
LONDON, UK / ACCESSWIRE / May 30, 2018 / If you want access to our free research report on Reata Pharmaceuticals, Inc. (NASDAQ: RETA), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=RETA as the Company's latest news hit the wire. On May 25, 2018, the Company announced that it has presented results from the ongoing, open-label, Phase-2 PHOENIX trial assessing bardoxolone methyl (bardoxolone) in patients with autosomal dominant polycystic kidney disease (ADPKD) and IgA nephropathy cohorts at the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA) meeting in Copenhagen.
- GlobeNewswire•2 months ago
Bardoxolone Methyl Improved Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease and IgA Nephropathy in the Ongoing Phase 2 Phoenix Study
Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced that positive interim data from the autosomal dominant polycystic kidney disease (ADPKD) and IgA nephropathy cohorts of the ongoing, open-label, Phase 2 PHOENIX trial are being presented by Pablo E. Pergola, M.D., Ph.D., Research Director, Renal Associates, PA, San Antonio, at the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA) meeting in Copenhagen.
- GlobeNewswire•2 months ago
Report: Developing Opportunities within AG Mortgage Investment Trust, Associated Banc-Corp, Reata Pharmaceuticals, Nathan's Famous, United Fire Group, and Intercept Pharmaceuticals — Future Expectations, Projections Moving into 2018
NEW YORK, May 18, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AG ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of RETA earnings conference call or presentation 9-May-18 12:00pm GMT
Q1 2018 Reata Pharmaceuticals Inc Earnings Call and Discussion of Development Programs
- GlobeNewswire•2 months ago
Reata Pharmaceuticals, Inc. Announces First Quarter 2018 Financial Results and an Update on Development Programs
CATALYST TRIAL IN CTD-PAH FINAL SAMPLE SIZE SET AT 200; TOP-LINE DATA EXPECTED IN THE FIRST HALF OF 2020. PHOENIX TRIAL INTERIM DATA FOR ADPKD AND IGA NEPHROPATHY COHORTS AT ERA-EDTA IN MAY; FULL DATA ...
- GlobeNewswire•3 months ago
Reata Announces New Preclinical Data Demonstrating the Potential of Omaveloxolone in the Treatment of Friedreich’s Ataxia and Other Severe Neurological Diseases
IRVING, Texas, April 24, 2018-- Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced new preclinical data demonstrating that omaveloxolone potently activates the Keap1/Nrf2 ...
- ACCESSWIRE•4 months ago
Wired News – Reata Pharma Reports Positive Top-line Data from its Phase-2 LARIAT Trial
Stock Monitor: Athersys Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 26, 2018 / Active-Investors.com has just released a free research report on Reata Pharmaceuticals, Inc. (NASDAQ: RETA ). ...
